Darwin Ye
YOU?
Author Swipe
View article: 451 Targeting a cancer cell interferon and TBK1 signaling axis to reverse acquired resistance to immune checkpoint blockade
451 Targeting a cancer cell interferon and TBK1 signaling axis to reverse acquired resistance to immune checkpoint blockade Open
View article: Targeting Interferon-Driven Inflammatory Memory Prevents Epigenetic Evolution of Cancer Immunotherapy Resistance
Targeting Interferon-Driven Inflammatory Memory Prevents Epigenetic Evolution of Cancer Immunotherapy Resistance Open
SUMMARY Acquired resistance is a growing obstacle to durable responses after cancer immune checkpoint blockade (ICB). The mechanisms by which heterogeneous tumors evolve under immunotherapy pressure and strategies targeting key populations…
View article: Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients
Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients Open
Persistent inflammation driven by cytokines such as type-one interferon (IFN-I) can cause immunosuppression. We show that administration of the Janus kinase 1 (JAK1) inhibitor itacitinib after anti–PD-1 (programmed cell death protein 1) im…
View article: Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer Open
Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, …
View article: RUNX1 is required in granulocyte–monocyte progenitors to attenuate inflammatory cytokine production by neutrophils
RUNX1 is required in granulocyte–monocyte progenitors to attenuate inflammatory cytokine production by neutrophils Open
The transcription factor RUNX1 is mutated in familial platelet disorder with associated myeloid malignancy (FPDMM) and in sporadic myelodysplastic syndrome and leukemia. RUNX1 was shown to regulate inflammation in multiple cell types. Here…
View article: RUNX1 is required in granulocyte-monocyte progenitors to attenuate inflammatory cytokine production by neutrophils
RUNX1 is required in granulocyte-monocyte progenitors to attenuate inflammatory cytokine production by neutrophils Open
The transcription factor RUNX1 is mutated in familial platelet disorder with associated myeloid malignancies (FPDMM) and in sporadic myelodysplastic syndrome and leukemia. RUNX1 regulates inflammation in multiple cell types. Here we show t…
View article: Durable Response and Improved CD8 T Cell Plasticity in Lung Cancer Patients After PD1 Blockade and JAK Inhibition
Durable Response and Improved CD8 T Cell Plasticity in Lung Cancer Patients After PD1 Blockade and JAK Inhibition Open
Persistent inflammation including type-one interferon (IFN-I) can cause immunosuppression. We show that delayed administration of the JAK1 inhibitor itacitinib after anti-PD1 improves immune function and anti-tumor response in mice, and re…
View article: The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function
The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function Open
View article: Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer Open
Although cancer immunotherapy with PD-(L)1 blockade is now routine treatment for patients with lung cancer, remarkably little is known about acquired resistance. We examined 1,201 patients with NSCLC treated with PD-(L)1 blockade to clinic…
View article: Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade Open